On Oct 16, major Wall Street analysts update their ratings for $Exelixis (EXEL.US)$, with price targets ranging from $27 to $34.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and adjusts the target price from $28 to $30.
Goldman Sachs analyst Chris Shibutani maintains with a sell rating.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and sets the target price at $32.
Citi analyst David Lebowitz maintains with a buy rating, and maintains the target price at $31.
Wells Fargo analyst Derek Archila maintains with a buy rating, and maintains the target price at $32.
Furthermore, according to the comprehensive report, the opinions of $Exelixis (EXEL.US)$'s main analysts recently are as follows:
The recent judgment regarding the Cabometyx MSN II case confirmed that the Malate Salt Patents remain valid and the '349 patent was neither infringed upon nor invalid. This outcome is seen as beneficial because it ensures patent protection until 2030. Although the decision falls shy of the more optimal scenario that could have extended the patent protection until 2032, it still represents a solid victory.
The affirmation of Cabometyx patent protection extending into 2030 has provided a new viewpoint for the company's future, with the progression of its pipeline now serving as a key narrative in driving the stock's value. The extended exclusivity period for Cabo and the improved prospects for the stock contribute to a more optimistic stance.
The recent legal ruling regarding MSN Laboratories litigation is considered a positive development for Exelixis, significantly enhancing the outlook for Cabometyx's patent exclusivity. This provides the company clear insights into prospective business development endeavors. The potential of zanzalintinib is viewed as a crucial element for the company's transition strategy beyond Cabometyx, with recent partnerships also garnering interest.
The affirmation of patent infringement and the validity of claims related to Exelixis' polymorph patents is seen as significantly positive. This development not only reinforces the intellectual protection for Cabometyx, potentially translating into considerable free cash flow, but also may lead to increased investor interest in other assets within the pipeline, including zanza.
Here are the latest investment ratings and price targets for $Exelixis (EXEL.US)$ from 13 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月16日，多家华尔街大行更新了$伊克力西斯 (EXEL.US)$的评级，目标价介于27美元至34美元。
摩根士丹利分析师Jeffrey Hung维持持有评级，并将目标价从28美元上调至30美元。
高盛集团分析师Chris Shibutani维持卖出评级。
美银证券分析师Jason Gerberry维持买入评级，目标价32美元。
花旗分析师David Lebowitz维持买入评级，维持目标价31美元。
富国集团分析师Derek Archila维持买入评级，维持目标价32美元。
此外，综合报道，$伊克力西斯 (EXEL.US)$近期主要分析师观点如下：
关于Cabometyx MSN II案件的最新裁决确认Malate盐专利仍然有效，'349专利既没有侵权也不无效。这一结果被视为有利，因为它确保了专利保护至2030年。尽管该决定未能达到将专利保护延长至2032年的更理想情况，但仍代表一次坚实的胜利。
Cabometyx专利保护延伸至2030年的确认为公司未来提供了新的视角，其产品线的进展现在成为推动股价价值的关键叙事。Cabometyx和股票前景的扩展独家期限有助于更加乐观的立场。
关于MSN实验室诉讼的最新法律裁决被视为Exelixis的积极发展，显著增强了Cabometyx专利独家性的前景。这为公司提供了对未来业务发展的清晰洞察。zanzalintinib的潜力被视为公司在Cabometyx之外过渡策略的关键要素，最近的合作伙伴也引起了关注。
对于Exelixis的多形态专利侵权和索赔有效性的确认被视为极为积极的。这一发展不仅加强了Cabometyx的知识产权保护，有望转化为可观的自由现金流，还可能导致投资者对管道内其他资产，包括zanza，产生更多兴趣。
以下为今日13位分析师对$伊克力西斯 (EXEL.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
